Oncogene - Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells

Colorectal cancer is one of the most common tumors among people over the age of 50. Although it is known to develop from small lesions or polyps, its exact causes are unknown—only a few risk factors are known—and it is usually treated with surgery, chemotherapy and radiotherapy, or biological therapies. Now, a study by the University of Barcelona reveals that the combination of palbociclib and telaglenastat, two drugs with complementary actions, could help improve the clinical treatment of this type of cancer, the third most common worldwide.

Synhale Therapeutics has acquired Telaglenastat, a key move to enhance the company's clinical programs for pulmonary hypertension, targeting unmet patient needs.